Use of Dalbavancin in Skin, Bone and Joint Infections: A Real-Life Experience in an Italian Center
Dalbavancin is a lipoglycopeptide approved for the treatment of acute bacterial skin and skin structure infections (ABSSSI). The aim of the study was to evaluate the efficacy and safety in all patients who received at least one administration of dalbavancin. Methods: We carried out a retrospective s...
| Main Authors: | , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2021-09-01
|
| Series: | Antibiotics |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2079-6382/10/9/1129 |
| _version_ | 1797520499568279552 |
|---|---|
| author | Lucia Brescini Filippo Della Martera Gianluca Morroni Sara Mazzanti Maria Di Pietrantonio Paolo Mantini Bianca Candelaresi Francesco Pallotta Silvia Olivieri Valentina Iencinella Sefora Castelletti Emanuele Cocci Rosaria G. Polo Salvatore Veccia Oscar Cirioni Marcello Tavio Andrea Giacometti |
| author_facet | Lucia Brescini Filippo Della Martera Gianluca Morroni Sara Mazzanti Maria Di Pietrantonio Paolo Mantini Bianca Candelaresi Francesco Pallotta Silvia Olivieri Valentina Iencinella Sefora Castelletti Emanuele Cocci Rosaria G. Polo Salvatore Veccia Oscar Cirioni Marcello Tavio Andrea Giacometti |
| author_sort | Lucia Brescini |
| collection | DOAJ |
| description | Dalbavancin is a lipoglycopeptide approved for the treatment of acute bacterial skin and skin structure infections (ABSSSI). The aim of the study was to evaluate the efficacy and safety in all patients who received at least one administration of dalbavancin. Methods: We carried out a retrospective study of the use of dalbavancin in 55 patients at the Azienda Ospedaliera Ospedali Riuniti Umberto I (Ancona, Italy) from February 2017 to May 2020 and compared “on label” and “off label” use of dalbavancin in ABSSSI and non-ABSSSI. Results: A total of 55 patients were included in the study. The median age was 61 years; 51% had ABSSSI; 24% had prosthetic joint infections, and 14% had osteomyelitis. A total of 53% received a single 1500 mg infusion of dalbavancin, and 18% received a second dose 14 days later; 24% of patients received further doses at 14-day intervals. In 91% of cases, patients achieved clinical objectives with dalbavancin: 96% of patients with ABSSSI and 69% of those with prosthetic joint infections. Conclusions: Dalbavancin was shown to have an excellent tolerability profile and to be a highly successful therapeutic approach even in those cases treated “off-label”. |
| first_indexed | 2024-03-10T07:57:40Z |
| format | Article |
| id | doaj.art-f27076b47da4445e9f6683e0c8b370cc |
| institution | Directory Open Access Journal |
| issn | 2079-6382 |
| language | English |
| last_indexed | 2024-03-10T07:57:40Z |
| publishDate | 2021-09-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Antibiotics |
| spelling | doaj.art-f27076b47da4445e9f6683e0c8b370cc2023-11-22T11:46:42ZengMDPI AGAntibiotics2079-63822021-09-01109112910.3390/antibiotics10091129Use of Dalbavancin in Skin, Bone and Joint Infections: A Real-Life Experience in an Italian CenterLucia Brescini0Filippo Della Martera1Gianluca Morroni2Sara Mazzanti3Maria Di Pietrantonio4Paolo Mantini5Bianca Candelaresi6Francesco Pallotta7Silvia Olivieri8Valentina Iencinella9Sefora Castelletti10Emanuele Cocci11Rosaria G. Polo12Salvatore Veccia13Oscar Cirioni14Marcello Tavio15Andrea Giacometti16Infectious Diseases Clinic, Ospedali Riuniti Umberto I, Via Conca 71, 60126 Torrette, AN, ItalyInfectious Diseases Clinic, Ospedali Riuniti Umberto I, Via Conca 71, 60126 Torrette, AN, ItalyDepartment of Biomedical Sciences and Public Health, Polytechnic University of Marche Medical School, Via Tronto 10/a, 60020 Torrette, AN, ItalyInfectious Diseases Clinic, Ospedali Riuniti Umberto I, Via Conca 71, 60126 Torrette, AN, ItalyInfectious Diseases Clinic, Ospedali Riuniti Umberto I, Via Conca 71, 60126 Torrette, AN, ItalyInfectious Diseases Clinic, Ospedali Riuniti Umberto I, Via Conca 71, 60126 Torrette, AN, ItalyInfectious Diseases Clinic, Ospedali Riuniti Umberto I, Via Conca 71, 60126 Torrette, AN, ItalyInfectious Diseases Clinic, Ospedali Riuniti Umberto I, Via Conca 71, 60126 Torrette, AN, ItalyInfectious Diseases Clinic, Ospedali Riuniti Umberto I, Via Conca 71, 60126 Torrette, AN, ItalyDepartment of Biomedical Sciences and Public Health, Polytechnic University of Marche Medical School, Via Tronto 10/a, 60020 Torrette, AN, ItalyInfectious Diseases, Ospedali Riuniti Umberto I, ViaConca 71, 60126 Torrette, AN, ItalyHospital Pharmacy, Ospedali Riuniti Umberto I, Via Conca 71, 60126 Torrette, AN, ItalyHospital Pharmacy, Ospedali Riuniti Umberto I, Via Conca 71, 60126 Torrette, AN, ItalyInfectious Diseases Clinic, Ospedali Riuniti Umberto I, Via Conca 71, 60126 Torrette, AN, ItalyInfectious Diseases Clinic, Ospedali Riuniti Umberto I, Via Conca 71, 60126 Torrette, AN, ItalyInfectious Diseases, Ospedali Riuniti Umberto I, ViaConca 71, 60126 Torrette, AN, ItalyInfectious Diseases Clinic, Ospedali Riuniti Umberto I, Via Conca 71, 60126 Torrette, AN, ItalyDalbavancin is a lipoglycopeptide approved for the treatment of acute bacterial skin and skin structure infections (ABSSSI). The aim of the study was to evaluate the efficacy and safety in all patients who received at least one administration of dalbavancin. Methods: We carried out a retrospective study of the use of dalbavancin in 55 patients at the Azienda Ospedaliera Ospedali Riuniti Umberto I (Ancona, Italy) from February 2017 to May 2020 and compared “on label” and “off label” use of dalbavancin in ABSSSI and non-ABSSSI. Results: A total of 55 patients were included in the study. The median age was 61 years; 51% had ABSSSI; 24% had prosthetic joint infections, and 14% had osteomyelitis. A total of 53% received a single 1500 mg infusion of dalbavancin, and 18% received a second dose 14 days later; 24% of patients received further doses at 14-day intervals. In 91% of cases, patients achieved clinical objectives with dalbavancin: 96% of patients with ABSSSI and 69% of those with prosthetic joint infections. Conclusions: Dalbavancin was shown to have an excellent tolerability profile and to be a highly successful therapeutic approach even in those cases treated “off-label”.https://www.mdpi.com/2079-6382/10/9/1129dalbavancinABSSSIprosthetic joint infectionsosteomyelitis |
| spellingShingle | Lucia Brescini Filippo Della Martera Gianluca Morroni Sara Mazzanti Maria Di Pietrantonio Paolo Mantini Bianca Candelaresi Francesco Pallotta Silvia Olivieri Valentina Iencinella Sefora Castelletti Emanuele Cocci Rosaria G. Polo Salvatore Veccia Oscar Cirioni Marcello Tavio Andrea Giacometti Use of Dalbavancin in Skin, Bone and Joint Infections: A Real-Life Experience in an Italian Center Antibiotics dalbavancin ABSSSI prosthetic joint infections osteomyelitis |
| title | Use of Dalbavancin in Skin, Bone and Joint Infections: A Real-Life Experience in an Italian Center |
| title_full | Use of Dalbavancin in Skin, Bone and Joint Infections: A Real-Life Experience in an Italian Center |
| title_fullStr | Use of Dalbavancin in Skin, Bone and Joint Infections: A Real-Life Experience in an Italian Center |
| title_full_unstemmed | Use of Dalbavancin in Skin, Bone and Joint Infections: A Real-Life Experience in an Italian Center |
| title_short | Use of Dalbavancin in Skin, Bone and Joint Infections: A Real-Life Experience in an Italian Center |
| title_sort | use of dalbavancin in skin bone and joint infections a real life experience in an italian center |
| topic | dalbavancin ABSSSI prosthetic joint infections osteomyelitis |
| url | https://www.mdpi.com/2079-6382/10/9/1129 |
| work_keys_str_mv | AT luciabrescini useofdalbavancininskinboneandjointinfectionsareallifeexperienceinanitaliancenter AT filippodellamartera useofdalbavancininskinboneandjointinfectionsareallifeexperienceinanitaliancenter AT gianlucamorroni useofdalbavancininskinboneandjointinfectionsareallifeexperienceinanitaliancenter AT saramazzanti useofdalbavancininskinboneandjointinfectionsareallifeexperienceinanitaliancenter AT mariadipietrantonio useofdalbavancininskinboneandjointinfectionsareallifeexperienceinanitaliancenter AT paolomantini useofdalbavancininskinboneandjointinfectionsareallifeexperienceinanitaliancenter AT biancacandelaresi useofdalbavancininskinboneandjointinfectionsareallifeexperienceinanitaliancenter AT francescopallotta useofdalbavancininskinboneandjointinfectionsareallifeexperienceinanitaliancenter AT silviaolivieri useofdalbavancininskinboneandjointinfectionsareallifeexperienceinanitaliancenter AT valentinaiencinella useofdalbavancininskinboneandjointinfectionsareallifeexperienceinanitaliancenter AT seforacastelletti useofdalbavancininskinboneandjointinfectionsareallifeexperienceinanitaliancenter AT emanuelecocci useofdalbavancininskinboneandjointinfectionsareallifeexperienceinanitaliancenter AT rosariagpolo useofdalbavancininskinboneandjointinfectionsareallifeexperienceinanitaliancenter AT salvatoreveccia useofdalbavancininskinboneandjointinfectionsareallifeexperienceinanitaliancenter AT oscarcirioni useofdalbavancininskinboneandjointinfectionsareallifeexperienceinanitaliancenter AT marcellotavio useofdalbavancininskinboneandjointinfectionsareallifeexperienceinanitaliancenter AT andreagiacometti useofdalbavancininskinboneandjointinfectionsareallifeexperienceinanitaliancenter |